A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

被引：14

作者：

Sekeres, Mikkael A. ^{[1
]}

Schuster, Michael W. ^{[2
]}

Joris, Magalie ^{[3
]}

Krauter, Jurgen ^{[4
]}

Maertens, Johan A. ^{[5
]}

Gyan, Emmanuel ^{[6
]}

Kovacsovics, Tibor ^{[7
]}

Verma, Amit ^{[8
]}

Vyas, Paresh ^{[9
]}

Wang, Eunice S. ^{[10
]}

Ma, Weidong Wendy ^{[11
]}

Zeremski, Mirjana ^{[11
]}

Kudla, Arthur ^{[11
]}

Chan, Geoffrey ^{[11
]}

Zeidan, Amer M. ^{[12
,13
]}

机构：

[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[2] SUNY Stony Brook, Hosp Canc Ctr, Stony Brook, NY USA

[3] CHU Amiens Picardie, Amiens, France

[4] Med Klin Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany

[5] UZ Leuven, Leuven, Belgium

[6] CHU Tours, Hop Bretonneau, Tours, France

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hematol & Oncol, Bronx, NY 10467 USA

[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Pfizer Oncol, New York, NY USA

[12] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA

[13] Yale Univ, Yale Canc Ctr, New Haven, CT USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124050

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

177

引用

页数：6

共 50 条

[1] A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Mikkael A. Sekeres
Michael Schuster
Magalie Joris
Jürgen Krauter
Johan Maertens
Dimitri Breems
Emmanuel Gyan
Tibor Kovacsovics
Amit Verma
Paresh Vyas
Eunice S. Wang
Keith Ching
Thomas O’Brien
Corrado Gallo Stampino
Weidong Wendy Ma
Arthur Kudla
Geoffrey Chan
Amer M. Zeidan
Annals of Hematology, 2022, 101 : 1689 - 1701
[2] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Sekeres, Mikkael A.
Schuster, Michael
Joris, Magalie
Krauter, Juergen
Maertens, Johan
Breems, Dimitri
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice S.
Ching, Keith
O'Brien, Thomas
Stampino, Corrado Gallo
Ma, Weidong Wendy
Kudla, Arthur
Chan, Geoffrey
Zeidan, Amer M.
ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
[3] Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence
Zeidan, Amer
Schuster, Michael
Joris, Magalie
Krauter, Juergen
Maertens, Johan
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice
Ma, Weidong
Zeremski, Mirjana
Kudla, Arthur
Chan, Geoffrey
Sekeres, Mikkael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S192
[4] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Borate, U.
Smith, B. D.
Gore, S.
Zeidan, A.
Savona, M.
Savoie, M. L.
Zhu, N.
Breems, D.
Zhang, X.
Shaik, M. N.
Rampersad, A.
Chan, G.
Woolfson, A.
Sekeres, M.
HAEMATOLOGICA, 2016, 101 : 73 - 74
[5] Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib plus Azacitidine
Wang, Eunice
Bell, Timothy
Zeidan, Amer
Bhattcharyya, Helen
Kudla, Arthur
Chan, Geoffrey
Sekeres, Mikkael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S191
[6] FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE
Madry, K.
Lis, K.
Zurawska, J.
Gorka, M.
Kacprzyk, P.
Dutka, M.
Rodzaj, M.
Bolkun, L.
Krochmalczyk, D.
Drozd-Sokolowska, J.
Waszczuk-Gajda, A.
Knopinska-Posluszny, W.
Kopinska, A.
Subocz, E.
Masternak, A.
Guzicka-Kazimierczak, R.
Gil, L.
Machowicz, R.
Dwilewicz-Trojaczek, J.
HAEMATOLOGICA, 2017, 102 : 490 - 490
[7] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
Zeidan, Amer Methqal
Schuster, Michael
Joris, Magalie
Krauter, Jurgen
Maertens, Johan
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice S.
Ma, Wendy
Zeremski, Mirjana
Kudla, Art
Chan, Geoffrey
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib plus azacitidine (AZA).
Wang, Eunice S.
Bell, Timothy
Zeidan, Amer Methqal
Bhattacharyya, Helen
Kudla, Art
Chan, Geoffrey
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Garcia-Manero, Guillermo
Gore, Steven D.
Cogle, Christopher
Ward, Renee
Shi, Tao
MacBeth, Kyle J.
Laille, Eric
Giordano, Heidi
Sakoian, Sarah
Jabbour, Elias
Kantarjian, Hagop
Skikne, Barry
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
[10] Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Vinod Pullarkat
Keith W. Pratz
Hartmut Döhner
Christian Recher
Michael J. Thirman
Courtney D. DiNardo
Pierre Fenaux
Andre C. Schuh
Andrew H. Wei
Arnaud Pigneux
Jun-Ho Jang
Gunnar Juliusson
Yasushi Miyazaki
Dominik Selleslag
Martha L. Arellano
Chenglong Liu
Jean A. Ridgeway
Jalaja Potluri
Jovita Schuler
Marina Konopleva
Blood Cancer Journal, 15 (1)

← 1 2 3 4 5 →